Personalized Cancer Treatment and Patient Stratification Using NGS and Other OMICs Data

• Broadcast Date: Thursday, January 31, 2013
• Time: 11am ET, 8am PT

REGISTRATION IS FREE

VIEW NOW

Rapidly evolving OMICs technologies have created significant opportunities for fundamental changes in drug discovery and healthcare, particularly in oncology. Cancer genome re-sequencing supported by gene expression profiling has provided a vast source of molecular data, potentially enabling selection of the most appropriate targets for individual treatment and drug response biomarkers for patient stratification. But availability of this data has required the development of analytical technology for its interpretation and clinical use.

During this webinar sponsored by ESMO and Thomson Reuters, development of a novel and comprehensive set of knowledge resources and analytical tools will be presented. These resources include a manually curated database of protein interactions and pathways, disease-associated gene and protein variants, medicinal chemistry and clinical trials databases, and an analytical toolkit consisting of statistical, functional analysis, and computational biology algorithms.

Informatics specialists and oncologists will come together to discuss applications for these resources. Clinical applications will focus on thoracic malignancies including current research regarding the use of molecular markers to personalize therapy with standard cytotoxic drugs in non-small-cell lung cancer including platinums and gemcitabine.

Utilization of this data in Europe and the U.S. will also be discussed in the context of its application in clinical translation to malignant mesothelioma treatment.

In this Webinar You Will Learn:

• How key aspects of MetaMiner (Oncology) from Thomson Reuters, a collaborative, cancer-specific industry-academic partnering program, has enabled target and drug response biomarker discovery
• How data analysis has been directly applied to personalized cancer therapy
• How molecular markers can be used to predict treatment toxicity
• How molecular markers are being applied to translational research in thoracic malignancies

Who Should Attend:

• Oncologists
• Internists
• Thoracic cancer specialists
• Tumor molecular biologists
• Bioinformaticists working in oncology
• Cancer drug developers

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

VIEW NOW